Effect of L-Carnitine on Biomarkers of Myocardial Reperfusion Injury in Patients With STEMI

PHASE2RecruitingINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

March 31, 2026

Conditions
Reperfusion Injury, MyocardialMyocardial Infarction
Interventions
DRUG

L-Carnitine

L-Carnitine 5 g intravenous administered as slow IV push over 2-3 minutes (L-Carnitine 1 gm / 5 mL Injection®, MEPACO, Egypt) and Carnitol 500 mg® Oral, Global Napi, Egypt)

DRUG

The standard care for the management of myocardial infarction post PCI

include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.

Trial Locations (1)

Unknown

RECRUITING

Ain Shams University Hospitals, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT06564909 - Effect of L-Carnitine on Biomarkers of Myocardial Reperfusion Injury in Patients With STEMI | Biotech Hunter | Biotech Hunter